Literature DB >> 18302153

Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer.

Neill Patani, Wen Jiang, Kefah Mokbel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18302153     DOI: 10.1002/ijc.23402

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  5 in total

1.  Nuclear osteopontin-c is a prognostic breast cancer marker.

Authors:  K Zduniak; P Ziolkowski; C Ahlin; A Agrawal; S Agrawal; C Blomqvist; M-L Fjällskog; G F Weber
Journal:  Br J Cancer       Date:  2015-01-27       Impact factor: 7.640

2.  Osteopontin splice variants are differential predictors of breast cancer treatment responses.

Authors:  Krzysztof Zduniak; Anil Agrawal; Siddarth Agrawal; Md Monir Hossain; Piotr Ziolkowski; Georg F Weber
Journal:  BMC Cancer       Date:  2016-07-11       Impact factor: 4.430

3.  Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.

Authors:  Amanda Psyrri; Konstantine T Kalogeras; Ralph M Wirtz; George Kouvatseas; Georgia Karayannopoulou; Anna Goussia; Flora Zagouri; Elke Veltrup; Eleni Timotheadou; Helen Gogas; Angelos Koutras; Georgios Lazaridis; Christos Christodoulou; George Pentheroudakis; Panagiota Economopoulou; Apostolos Laskarakis; Petroula Arapantoni-Dadioti; Anna Batistatou; Maria Sotiropoulou; Gerasimos Aravantinos; Pavlos Papakostas; Paris Kosmidis; Dimitrios Pectasides; George Fountzilas
Journal:  J Transl Med       Date:  2017-02-13       Impact factor: 5.531

4.  Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer.

Authors:  Xiaojian Tang; Jianfang Li; Beiqin Yu; Liping Su; Yingyan Yu; Min Yan; Bingya Liu; Zhenggang Zhu
Journal:  Int J Biol Sci       Date:  2012-12-20       Impact factor: 6.580

5.  Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.

Authors:  Kinga Walaszek; Elyse E Lower; Piotr Ziolkowski; Georg F Weber
Journal:  Br J Cancer       Date:  2018-10-24       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.